贝沙格列净
| CAS号 | 1118567-05-7 | 货号 | BCP03928 |
| 中文名 | 贝沙格列净 | ||
| 英文名 | EGT1442 | ||
| 中文别名 | |||
| 英文别名 | EGT-1442;EGT 1442;Bexagliflozin; | ||
| 分子式 | C24H29ClO7 | 分子量 | 464.94 |
| 生物活性 | Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity. In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis. | ||
| 信号通路 | Ion Channel/Membrane Transporter GPCR/G Protein | ||
| 靶 点 | SGLT | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！